Trial · NCT01360424
Teriparatide Treatment in Patients With Inherited Osteoporosis
NCT01360424, Phase 4, Completed, Helsinki University Central Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Teriparatide Treatment in Patients With Inherited Osteoporosis. Trials, record NCT01360424. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01360424
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Teriparatide Treatment in Patients With Inherited Osteoporosis
- NCT number
- NCT01360424
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 6 participants, actual
- Lead sponsor
- Helsinki University Central Hospital
- Conditions
- Osteoporosis
- Interventions
- Teriparatide
- First posted
- 2011-05-25
- Last updated
- 2015-09-29
- Other registries' IDs
- eudract:2010-019297-32
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change from baseline in lumbar bone mineral density (BMD) | 0, 12 and 24 months | The primary outcome measure is the change in lumbar BMD measured with dual-energy X-ray absorptiometry (DXA) during the 24 months treatment period. |
| Secondary | Change from baseline in whole body bone mineral density (DXA) | 0,12 and 24 months | |
| Secondary | Change from baseline in hip bone mineral density (DXA) | 0,12 and 24 months | |
| Secondary | Change from baseline in histomorphometry of bone biopsy samples | 0 and 24 months | includes e.g following parameters: Bone volume (BV/TV, %); Osteoid volume (OV/BV, %); Trabecular thickness (Tb.Th, um); Osteoid surface (OS/BS, %); Osteoblast surface (Ob.S/BS, %); Eroded surface (ES/BS, %); Osteoclast surface (Oc.S/BS, %); Mineral apposition rate (MAR, um/day); Mineralizing surface (MS/BS, %) |
| Secondary | Change from baseline in bone microarchitecture assessed by micro computed tomography of bone biopsy samples | 0 and 24 months | includes e.g following parameters: bone volume (BV, mm3); relative bone volume (BV/TV, %); connectivity density, (Conn.D., 1/mm3); trabecular number (DT-Tb.N, 1/mm); trabecular thickness (DT-Tb.Th, mm) |
| Secondary | Change from baseline in peripheral quantitative computed tomography (pQCT) measured cortical and trabecular volumetric bone mineral density of tibia and radius | 0,12 and 24 months | |
| Secondary | Number of vertebral fractures (spine X-ray) | 24 months | |
| Secondary | Change from baseline in serum procollagen type I N-terminal propeptide (PINP) | 0,3,6,12 and 24 months | |
| Secondary | Change from baseline in serum type I collagen C-telopeptides (CTX) | 0,3,6,12 and 24 months | |
| Secondary | Change from baseline in serum osteocalcin | 0,3,6,12 and 24 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01360424
GET https://conductscience.org/api/trials/v1/NCT01360424/registered